Condition: Obesity · Sponsor: Centre Hospitalier Universitaire de Nice
Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.
This description comes directly from the study's public registry record.
ROUX Christian, PhD · +3349209220 · roux.c@chu-nice.fr
Iannelli Antonio, PhD · chirurgiedigestive@priannelli.com
Always discuss trial participation with your own doctor first.
| CHU de Nice - Hôpital de l'Archet | Nice, Alpes-maritimes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06278285